SOURCE: JORDAN SCHACHTEL
In reviewing SEC filings, The Dossier has found that the Gates Foundation’s holdings in BioNTech went from 1,038,674 shares to 148,674 shares over the course of the third quarter of 2021, downsizing the Gates position in the mRNA vaccine manufacturer by 86 percent of shares held.
As you can see below, Gates just so happened to time the market perfectly, selling the shares during BioNtech’s best performing quarter.
In September of 2019, just months before Covid hysteria made its way through the world, The Gates Foundation secured its shares in the Pfizer vaccine partner through a pre-IPO equity deal with an agreed upon purchase price of $18.10 per share. With an average sale price of around $300 per share in Q3 of 2021, this means that the Gates Foundation banked roughly $260 million in cash from the sale, with $242 million being untaxed profit, given that the money was invested through the foundation. And that doesn’t account for the additional 2 million shares that the Gates Foundation sold prior to that from its original pre-IPO equity investment. In the Q3 2021 sale, the Gates Foundation secured a return of over 15 times more than its initial investment.
Over the next quarter, Gates unloaded 1.4 million shares of Curevac, another Germany-based mRNA company that has partnered with several mRNA shot manufacturers, banking an estimated $50 million.
After selling his mRNA company shares, Gates changed his tune on the tech behind the “miracle cure.” Gates, who once claimed that vaccination with mRNA shots had a preventive effect and “helps your heart,” began to criticize the experimental injections.